Company news

CNS Pharmaceuticals, Inc. news in 2020

CNS Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.

View company

CNS Pharmaceuticals Announces Pricing of $10.0 Million Public Offering

December 22, 2020

CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8: 30am ET

December 17, 2020

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

December 16, 2020

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

December 16, 2020

CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

November 16, 2020

CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4: 30 PM ET Today

November 11, 2020

CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

November 8, 2020

CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

October 28, 2020

CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

October 19, 2020

CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

October 8, 2020

CNS Pharmaceuticals Achieves Critical Manufacturing Milestone

September 30, 2020

CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin

September 23, 2020

CNS Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 16, 2020

CNS Pharmaceuticals Announces US Drug Manufacturing Milestones

September 2, 2020

CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board

August 26, 2020

CNS Provides FDA Update on IND Filing

August 24, 2020

CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

August 19, 2020

CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

August 10, 2020

CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

July 14, 2020

CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers

July 7, 2020

CNS Pharmaceuticals Engages Berry Consultants to Advise Phase 2 Trial Design

June 29, 2020

CNS Announces the FDA has Granted Orphan Drug Designation for Brain Cancer Drug Berubicin

June 10, 2020

CNS Announces Highlights from Annual Meeting of Shareholders

June 8, 2020

CNS Pharmaceuticals Announces Sponsored Research Agreement with MD Anderson for Potential Cancer Treatment Technologies

May 27, 2020

CNS Provides Update on Development Agreement for WP1122

May 26, 2020

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 26, 2020

CNS Announces Nasdaq Trading Halt Pending Receipt of Additional Information

May 17, 2020

CNS Pharmaceuticals Announces Trading Halt

May 3, 2020

CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin

April 22, 2020

CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

April 14, 2020

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

April 12, 2020

CNS Pharmaceuticals Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates for a Range of Viruses including Coronavirus for International Markets

March 22, 2020

CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results

March 11, 2020

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020

March 4, 2020

CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free

March 2, 2020

CNS Pharmaceuticals to Ring Nasdaq Stock Market Opening Bell on March 3

February 26, 2020

CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

February 10, 2020

CNS Pharmaceuticals Announces Completion of GMP Manufacturing

February 3, 2020

CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance

January 27, 2020

CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin

January 13, 2020

CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline

January 12, 2020

Decks in 2020